Division of Cell Recognition Study, Institute of Molecular Biomembrane and Glycobiology, Tohoku Medical and Pharmaceutical University, 4-4-1 Komatsushima, Aoba-ku, Sendai 981-8558, Japan.
Chemiluminescent Reagents Department, R&D Section, Kagamida Factory, DENKA SEIKEN Co. Ltd., 1359-1 Kagamida, Kigoshi Gosen-shi, Niigata 959-1695, Japan.
Glycobiology. 2020 Sep 28;30(10):802-816. doi: 10.1093/glycob/cwaa029.
New treatment protocols are aiming to reduce the dose of the multitargeted tyrosine kinase inhibitor sunitinib, as sunitinib elicits many adverse effects depending on its dosage. Silurus asotus egg lectin (SAL) has been reported to enhance the incorporation of propidium iodide as well as doxorubicin into Burkitt's lymphoma Raji cells through binding to globotriaosylceramide (Gb3) on the cell surface. The objective of this study was to examine whether SAL enhances the cytotoxic effect of sunitinib in Gb3-expressing HeLa cells. Although the treatment with SAL delayed the cell growth and enhanced the propidium iodide uptake, cell death accompanied by membrane collapse was not observed. The viability of sunitinib-treated HeLa cells was significantly reduced when the treatment occurred in combination with SAL compared to their separate usage. Sunitinib uptake significantly increased for 30 min in SAL-treated cells, and this increment was almost completely abolished by the addition of L-rhamnose, a hapten sugar of SAL, but not by D-glucose. After removal of SU from the medium, the intracellular sunitinib level in SAL-treated cells was higher than in untreated cells for 24 h, which was not observed in Gb3-deficient HeLa cells. Furthermore, we observed that SAL promoted the formation of lysosome-like structures, which are LAMP1 positive but not acidic in HeLa cells, which can trap sunitinib. Interestingly, SAL-induced vacuolation in HeLa cells was not observed in another Gb3 positive Raji cells. Our findings suggest that SAL/Gb3 interaction promoted sunitinib uptake and suppressed sunitinib excretion and that sunitinib efficiently exerted cytotoxicity against HeLa cells.
新的治疗方案旨在降低多靶点酪氨酸激酶抑制剂舒尼替尼的剂量,因为舒尼替尼的剂量会引起许多不良反应。据报道,鲇鱼卵 lectin(SAL)通过与细胞表面的神经节苷脂 Gb3 结合,增强了碘化丙啶以及阿霉素掺入伯基特淋巴瘤 Raji 细胞。本研究旨在研究 SAL 是否增强了 Gb3 表达的 HeLa 细胞中舒尼替尼的细胞毒性作用。尽管 SAL 处理延迟了细胞生长并增强了碘化丙啶摄取,但未观察到伴随细胞膜崩溃的细胞死亡。与单独使用相比,当 SAL 与舒尼替尼联合使用时,舒尼替尼处理的 HeLa 细胞的活力显著降低。SAL 处理的细胞中,舒尼替尼摄取在 30 分钟内显著增加,并且这种增加几乎完全被 SAL 的半抗原糖 L-鼠李糖消除,但不是 D-葡萄糖。从培养基中去除 SU 后,SAL 处理的细胞中的细胞内舒尼替尼水平在 24 小时内高于未处理的细胞,而在 Gb3 缺陷的 HeLa 细胞中则未观察到这种情况。此外,我们观察到 SAL 促进了溶酶体样结构的形成,该结构在 HeLa 细胞中为 LAMP1 阳性但不为酸性,可以捕获舒尼替尼。有趣的是,在另一个 Gb3 阳性 Raji 细胞中,未观察到 SAL 诱导的 HeLa 细胞空泡化。我们的发现表明,SAL/Gb3 相互作用促进了舒尼替尼的摄取,抑制了舒尼替尼的排泄,并且舒尼替尼对 HeLa 细胞具有有效的细胞毒性作用。